Parilman & Associates Alerts Public to FDA Advisory Committee Hearing Regarding Potential Risks of Testosterone Drugs

Share Article

The testosterone replacement therapy lawyers at Parilman & Associates, whose law firm Web site URL can be found at, represent consumers who have been injured by defective products and dangerous medications. The attorneys at the firm hereby alert the public of a forthcoming FDA Advisory Committee meeting that will involve a discussion of the potential risks of testosterone replacement therapy medications.

The testosterone replacement therapy attorneys at Parilman & Associates have been representing clients across the country allegedly injured by using defective and dangerous medications. As such, the attorneys at the firm keep a close eye on developments regarding any widely-used medications. The firm hereby alerts the public that the United States Food and Drug Administration, or FDA, will convene an Advisory Committee hearing in September. That meeting will discuss the potential risks associated with the use of low testosterone medication.

The FDA’s announcement of the meeting can be found on their Web site here. The meeting will be held on September 17, 2014 at the College Park Marriott Hotel and Conference Center, which is located at 3501 University Blvd. East, Hyattsville, Maryland. The meeting will begin at 8:00 a.m. and it will end at 5:00 p.m. The meeting will involve the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, both arms of the FDA.

The agenda for the meeting that was published by the FDA states that the “committees will discuss the appropriate indicated population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with this use.” These adverse cardiovascular outcomes include heart attacks and strokes. Anyone interested in presenting written materials or speaking at the meeting can contact the FDA for further information. The notice for this hearing was posted on July 17, 2014.

This meeting is being held after the FDA released a Safety Announcement earlier this year that concerned the use of testosterone replacement therapy medications. In that Safety Announcement, the FDA states that, “We have been monitoring this risk and decided to reassess this safety issue based on the recent publication of two separate studies that each suggested an increased risk of cardiovascular events among groups of men prescribed testosterone therapy.” A link to that Safety Announcement published by the FDA can be found here.

The testosterone replacement therapy lawyers at Parilman & Associates want to make sure that the public is aware of this hearing. The reason is that people who are using these medications currently could be affected by the outcome. Those who have been using testosterone replacement therapy medications and who believe that they have been harmed as a result of them should seek immediate legal advice.

About Parilman & Associates
Parilman & Associates is a nationwide law firm that represents individuals and classes of consumers who have been injured by defective products. These products include defective consumer products, medical devices and defective medications. The firm also represents clients who have been injured by exposure to asbestos and those who have been wrongfully harmed in different types of accidents. The firm’s Facebook profile can be found at The firm can also be reached by phone at 800-800-DRUG.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joshua Parilman
Visit website